COUNSELING TOBI® PODHALER® PATIENTS
Set treatment expectations with your patients
Cough is a common symptom of cystic fibrosis.1
In a clinical trial, patients taking TOBI Podhaler reported a higher incidence of cough than patients taking TOBI® (Tobramycin Inhalation Solution, USP) during the first week of active treatment.1
After the first week of treatment in the same study, the time to first cough was similar in patients taking TOBI Podhaler and patients taking TOBI.1
Five percent of patients taking TOBI Podhaler discontinued due to cough compared with 1% of patients taking TOBI.1
Patients and caregivers should be initially trained by their healthcare provider on the proper use of TOBI Podhaler.
In addition to the training you provide your patients, advise them to read the Patient Information and the full Instructions for Use. Please see additional information and helpful tips below.